The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what FDA Peptide Ban Lifted: Legit Compounding Pharmacies Now Regulate Julian Becerra posted on the topic LinkedIn FDA Peptide Reclassification 2026: What It Actually Means The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion Peptide Research Overview Mechanisms, Applications & Insights